LearnGlossaryMarketStocksSuperinvestorsSign in

BCAB

BioAtla, Inc.

Healthcare · $3M market cap

Verdict

We can't put a fair value on BCAB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-65.9% a year✗
Sales growth-21.2% a year✗
Free cash flow growth—?
Return on invested capital-36.0%✗

Follow BCAB

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Vasquez Christian

Chief Financial Officer · 2026-08-31

Tax withholding

$120

SHORT JAY M PHD

Chief Executive Officer · 2026-08-31

Tax withholding

$438

Sievers Eric

Chief Medical Officer · 2026-08-31

Tax withholding

$226

About BioAtla, Inc.

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works